RxDoctor Payments Data

Karen McCutcheon, MD

Family Medicine · Murrells Inlet, SCNPI 1881613610

Payments from drug & device makers

$14,134in general payments, 2019–2025

Across 719 payments — averaging $19.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$2K
  • Novo Nordisk$1K
  • GSK$846
  • Lilly USA, LLC$831
  • Amgen$783
  • plus $7K from 49 others

What the payments were for

  • Food & beverage$13,97999%
  • Education$1561%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,134 in reported general payments places this provider in the 95th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$225,640
Medicare patients
648
Services billed
7,690

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide117$184,298
EliquisApixaban106$125,119
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$54,256
FarxigaDapagliflozin Propanediol31$45,768
TrulicityDulaglutide26$39,125
JanuviaSitagliptin Phosphate21$32,522
XareltoRivaroxaban17$26,945
JardianceEmpagliflozin17$22,581
RybelsusSemaglutide17$22,020
JanumetSitagliptin Phos/Metformin Hcl13$20,945
MyrbetriqMirabegron17$12,318
SynthroidLevothyroxine Sodium103$10,647
Aimovig AutoinjectorErenumab-Aooe13$9,626
Atorvastatin Calcium739$9,017
Breo ElliptaFluticasone/Vilanterol12$8,098

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,299$206,318134 claims
PfizerEliquis, Premarin$273$132,166120 claims
GSKTrelegy Ellipta, Breo Ellipta$846$62,35452 claims
MerckJanuvia, Janumet$131$53,46734 claims
AstraZenecaFarxiga, Symbicort$1,787$51,56942 claims
Lilly USA, LLCTrulicity$831$39,12526 claims
Johnson & JohnsonXarelto$117$26,94517 claims
Boehringer IngelheimJardiance$231$22,58117 claims
Astellas Pharma US IncMyrbetriq$531$12,31817 claims
AbbVieSynthroid$2,031$10,647103 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Murrells Inlet

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →